PHF20 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19730381	1.00	1/20
SCHEMBL27223881	0.85	1/20
SCHEMBL29613516	0.85	1/20
SCHEMBL24510772	0.75	1/20
SCHEMBL29664786	0.72	1/20
SCHEMBL24510615	0.71	1/20
SCHEMBL24510649	0.71	1/20
SCHEMBL29613411	0.71	1/20
SCHEMBL27223857	0.63	1/20
SCHEMBL29613449	0.63	1/20
SCHEMBL399014	0.59	1/20
SCHEMBL911014	0.57	1/20
SCHEMBL30475010	0.56	1/20
SCHEMBL12381279	0.54	1/20
SCHEMBL30797925	0.54	1/20
SCHEMBL24510651	0.53	1/20
SCHEMBL3107714	0.52	1/20
SCHEMBL13157828	0.52	1/20
SCHEMBL4601494	0.51	1/20
SCHEMBL16420772	0.51	1/20

Clinical trials — most relevant to PHF20 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein	PHASE1	COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML	PHASE1	COMPLETED
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)	PHASE1	NOT_YET_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome	nan	COMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)	nan	UNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PHF20 binder may also engage these)

Protein	Name	Similarity
Q8BLG0	—	1.000	Q8BLG0 →
A8MW92	—	1.000	A8MW92 →
Q8CCJ9	—	1.000	Q8CCJ9 →
Q6KAQ7	—	0.999	Q6KAQ7 →
Q4V9H5	—	0.997	Q4V9H5 →
Q28DE6	—	0.996	Q28DE6 →
A3KMW7	—	0.995	A3KMW7 →
Q925H1	—	0.995	Q925H1 →
Q8BM75	—	0.995	Q8BM75 →
O54963	—	0.995	O54963 →
Q8CCG4	—	0.995	Q8CCG4 →
Q71F56	—	0.994	Q71F56 →
Q8NEZ4	—	0.994	Q8NEZ4 →
Q5SW75	—	0.994	Q5SW75 →
Q90YL3	—	0.994	Q90YL3 →
B2RXH4	—	0.994	B2RXH4 →
Q5ZJK5	—	0.994	Q5ZJK5 →
E1BLP6	—	0.994	E1BLP6 →
Q5EXX3	—	0.994	Q5EXX3 →
Q9UHV7	—	0.994	Q9UHV7 →
Q9DB00	—	0.994	Q9DB00 →
Q80YR5	—	0.993	Q80YR5 →
Q9JIC3	—	0.993	Q9JIC3 →
Q6UB99	—	0.993	Q6UB99 →
O35914	—	0.993	O35914 →
A5X7A0	—	0.993	A5X7A0 →
Q62947	—	0.993	Q62947 →
Q8BLR5	—	0.993	Q8BLR5 →
Q498M5	—	0.993	Q498M5 →
Q6IR42	—	0.993	Q6IR42 →